Therapeutic use of at least one botulinum neurotoxin in the treatment of pain induced by at least one anti-neoplastic agent

• US 20100068231A1
• Filed: 10/26/2007
• Published: 03/18/2010
• Est. Priority Date: 10/27/2006
• Status: Active Grant

• Current Assignee: Ipsen Pharma Sas (Ipsen Sa)
• Original Assignee: Ipsen Pharma Sas (Ipsen Sa)
• Inventors: Chabrier De Lassauniere, Pierrre-Etienne, Favre, Christine, Auguet, Michel
• Granted Patent: US 8,273,359 B2
• Time in Patent Office: Days
• US Class Current: 424/239.100
• CPC Class Codes: A61K 38/4893 Botulinum neurotoxin (3.4.24.69)
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 25/02 for peripheral neuropathies
• CPC Class Codes: A61P 25/04 Centrally acting analgesics, e.g. opioids
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 35/00 Antineoplastic agents

Abstract

The present invention relates to a method of treating or preventing pain or pains induced by an anti-neoplastic agent, comprising the step of administering an effective amount of at least one botulinum neurotoxin to a patient in need thereof.

Claims

1-16. -16. (canceled)

17. A method of treating or preventing systemic post-chemotherapy pain or pains, comprising the step of administering a localized dose of an effective amount of at least one botulinum neurotoxin to a patient in need thereof.

18. The method of claim 17, wherein said post-chemotherapy pain or pains are induced by an anti-neoplastic agent or a salt thereof.

19. The method of claim 18, wherein said anti-neoplastic agent or salt thereof is a taxane, a platinum salt, or any combination thereof.

20. The method of claim 18, wherein said anti-neoplastic agent or salt thereof is docetaxel, paclitaxel (taxol), or any combination thereof.

21. The method of claim 19, wherein said anti-neoplastic agent or salt thereof is cisplatin, oxaliplatin, carboplatin, or any combination thereof.

22. The method of claim 18, wherein said anti-neoplastic agent or salt thereof is vincristine, vinblastine, etoposide, teniposide, Ara-A (adenoside-arabinoside), Ara-C (cytarabine), fluorouracil, procarbazine, vinorelbine, gemcitabine, or a mixture of paclitaxel and carboplatin,

paclitaxel and an anthracycline,

paclitaxel, carboplatin, and gemcitabine,

paclitaxel and estramustine,

docetaxel and cisplatin,

docetaxel and doxorubicin,

docetaxel and vinorelbine,

docetaxel and trastuzumab,

docetaxel and capecitabine,

cisplatin and cyclophosphamide,

cisplatin and irinotecan,

carboplatin and topotecan,

carboplatin and estramustine,

etoposide and estramustine, or

vinblastine and estramustine.

23. The method of claim 17, comprising administering said botulinum neurotoxin

by intramuscular, intradermal, or subcutaneous route.

24. The method of claim 17, wherein said botulinum neurotoxin is of type A, A1, A2, B, C, C1, D, E, F or G.

25. The method of claim 24, wherein said botulinum neurotoxin is of type A1.

26. The method of claim 17, further comprising combining said botulinum neurotoxin with at least one polysaccharide.

27. The method of claim 26, wherein said at least one polysaccharide is 2-hydroxy-ethyl starch.

28. The method of claim 17, wherein said botulinum neurotoxin is a modified botulinum neurotoxin comprising at least one deleted, modified or replaced amino acid.

29. The method of claim 17, further comprising combining said botulinum neurotoxin with at least one surfactant.

30. The method of claim 29, wherein the at least one surfactant is a cationic, anionic, or non-ionic surfactant.

31. The method of claim 29, wherein the at least one surfactant is non-ionic and a polysorbate.

32. The method of claim 17, further comprising administering said botulinum neurotoxin at a dose between 0.01 to 1500 U.

33. The method of claim 17, wherein said patient experiences post-chemotherapy pain or pains resulting from the treatment of cancers of the colon, rectum, breast, lungs, pancreas, testicles, kidney, uterus, ovary, prostate, skin, bones, or spinal cord or sarcomas, carcinomas, fibroadenomas, neuroblastomas, leukaemias, lymphomas, or melanomas.